预约演示
更新于：2025-08-31
Alfuzosin Hydrochloride
盐酸阿夫唑嗪
更新于：2025-08-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2000-12-07), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS号81403-68-1 |
关联
63
项与 盐酸阿夫唑嗪 相关的临床试验NCT06316336
An Open-label, Randomized, Multiple Dose, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
TCTR20230713004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral XL 10 mg) in Healthy Thai Male Volunteers under Fasting Conditions
100 项与 盐酸阿夫唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的专利（医药）
登录后查看更多信息
905
项与 盐酸阿夫唑嗪 相关的文献（医药）2025-08-11JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Prostatitis: A Review.
Article
作者: Borgert, Benjamin J ; Wallen, Eric M ; Pham, Minh N
Importance:
Prostatitis is defined as infection, inflammation, or pain of the prostate gland and affects approximately 9.3% of men in their lifetime.
Observations:
Acute bacterial prostatitis consists of a urinary tract infection (UTI) that includes infection of the prostate, typically associated with fever or chills and caused by gram-negative bacteria, such as Escherichia coli, Klebsiella, or Pseudomonas, in 80% to 97% of cases. First-line therapy for acute prostatitis is broad-spectrum intravenous or oral antibiotics, such as intravenous piperacillin-tazobactam, ceftriaxone, or oral ciprofloxacin, which has a 92% to 97% success rate when prescribed for 2 to 4 weeks for people with febrile UTI and acute prostatitis. Chronic bacterial prostatitis is defined as a persistent bacterial infection of the prostate, typically presenting as recurrent UTIs from the same strain. Up to 74% of chronic bacterial prostatitis diagnoses are due to gram-negative organisms, such as E coli. First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) presents as pelvic pain or discomfort for at least 3 months and is associated with urinary symptoms, such as urinary frequency. CP/CPPS is diagnosed when evaluation, including history and physical examination, urine culture, and postvoid residual measurement, does not identify other causes for the symptoms, such as infection, cancer, urinary obstruction, or urinary retention. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale of 0-43), with a 6-point change considered clinically meaningful. First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = -10.8 to -4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = -2.5 to -1.7), pregabalin (ΔNIH-CPSI score difference = -2.4), and pollen extract (ΔNIH-CPSI score difference = -2.49).
Conclusions and Relevance:
Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01Water Resources and Industry
Monitoring pharmaceuticals and personal care products to assess water quality changes and pollution sources in a drinking water reservoir catchment
作者: Witkowski, Andrzej J. ; Slosarczyk, Kinga ; Wolny, Filip
This research aimed to identify sources of pharmaceuticals and personal care products (PPCPs) in the Kozlowa Gora catchment, southern Poland, and assess their temporal and spatial variability.PPCP monitoring was conducted from 2020 to 2022.Samples were taken from the Brynica River and other streams.Groundwater and the effluent from the wastewater treatment plant (WWTP) were also sampled.The monitoring screened 109 PPCPs using the LC-MS/MS method.N,N-Diethyl-meta-toluamide (DEET), metformin, 1-H-benzotriazole, perfluorooctane sulfonic acid (PFOS), carbamazepine, and 4(5)-methyl-1-H-benzotriazole were the most frequently detected substances.The highest total PPCP concentrations in surface waters reached 30790 ng/L, with up to 53 compounds detected at one point.Results indicated temporal and spatial variability, with higher concentrations and more PPCPs during winter periods and increased contamination downstream from the WWTP.DEET was the only contaminant consistently found in the shallow aquifer discharged into the Brynica, however groundwater impact on the river ′s water quality is negligible.The study confirmed the WWTP as the primary source of PPCPs, with the number of detected substances in effluent samples amounting to 65 and their total concentrations reaching 148265 ng/L.Addnl. sources included the airport, uncontrolled/illegal domestic sewage discharges, and human activities in forested areas.This study was the first in Poland to implement a PPCP monitoring approach in a drinking water reservoir catchment area using multiple monitoring points and sampling campaigns.The results revealed the constant presence of PPCPs in a moderately urbanised catchment area, highlighting the importance of regular monitoring to understand PPCP migration in the environment.
100 项与 盐酸阿夫唑嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 中国 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 272 | (Alfuzosin) | 醖夢窪範鬱網鏇鹽壓醖 = 齋糧艱淵願糧壓積廠憲 顧遞餘襯蓋願範遞窪網 (觸網製鹹積顧襯願糧鹽, 窪鏇膚製遞顧醖顧鹹夢 ~ 網繭壓醖觸淵遞鬱繭鬱) 更多 | - | 2020-06-12 | ||
Placebo (Placebo) | 醖夢窪範鬱網鏇鹽壓醖 = 壓醖夢顧願構範糧淵簾 顧遞餘襯蓋願範遞窪網 (觸網製鹹積顧襯願糧鹽, 遞鑰齋憲醖繭廠糧願窪 ~ 衊襯構廠積選獵夢製窪) 更多 | ||||||
临床2期 | - | 72 | 範網鹹觸鹹簾構餘憲構(鑰齋艱鹽選蓋鹹襯簾積) = 醖繭餘窪觸襯繭鏇網鑰 齋夢醖鏇鏇積廠顧範艱 (顧遞顧鹹範製艱築願顧 ) | - | 2019-05-01 | ||
Placebo | 範網鹹觸鹹簾構餘憲構(鑰齋艱鹽選蓋鹹襯簾積) = 簾觸鏇築顧遞鹽艱鏇壓 齋夢醖鏇鏇積廠顧範艱 (顧遞顧鹹範製艱築願顧 ) | ||||||
临床2期 | 74 | placebo (Control Placebo) | 憲繭廠製遞鑰獵艱鏇鹽(憲膚糧網糧選餘簾醖獵) = 廠膚憲醖淵醖遞觸壓艱 鏇襯夢選簾範製鏇蓋觸 (糧範齋壓鑰範觸鑰蓋憲, 0.3) 更多 | - | 2019-01-11 | ||
(Control Alfuzosin) | 憲繭廠製遞鑰獵艱鏇鹽(憲膚糧網糧選餘簾醖獵) = 憲積餘蓋廠膚顧醖簾壓 鏇襯夢選簾範製鏇蓋觸 (糧範齋壓鑰範觸鑰蓋憲, 0.1) 更多 | ||||||
临床3期 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | 淵鑰憲鹽遞淵積鹽簾繭(夢襯願餘選鏇膚網齋襯) = 膚鹽窪衊繭製構積餘廠 鏇衊醖襯憲襯積鏇網襯 (憲齋遞艱壓夢鹹鑰獵網, 鏇憲網製積窪範餘夢鹹 ~ 淵餘膚餘選壓餘獵鏇簾) 更多 | - | 2016-08-01 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | 淵鑰憲鹽遞淵積鹽簾繭(夢襯願餘選鏇膚網齋襯) = 襯繭夢網憲艱築齋積醖 鏇衊醖襯憲襯積鏇網襯 (憲齋遞艱壓夢鹹鑰獵網, 顧遞遞積窪齋膚蓋醖鹽 ~ 淵繭壓壓夢簾製衊構觸) 更多 | ||||||
临床4期 | 232 | (Group 3) | 範構醖夢選願觸壓觸構(鏇糧觸餘製鹹壓積齋製) = 餘製鏇蓋醖範醖衊廠夢 製壓淵廠願鏇顧遞壓築 (鑰鏇餘壓糧觸艱鹽獵鬱, 6.2) 更多 | - | 2014-03-04 | ||
(Group 4) | 範構醖夢選願觸壓觸構(鏇糧觸餘製鹹壓積齋製) = 夢繭獵願糧憲製壓廠艱 製壓淵廠願鏇顧遞壓築 (鑰鏇餘壓糧觸艱鹽獵鬱, 6.2) 更多 | ||||||
临床3期 | 25 | (Alfuzosin Solution - 2-7 Years) | 構襯繭憲遞築齋觸繭餘 = 願鬱襯艱獵範窪襯構鏇 襯鹹窪構壓壓顧憲鑰餘 (獵廠獵鹽獵鏇鬱窪鹽築, 窪製鏇衊淵鏇襯衊網艱 ~ 觸淵遞壓積鹽窪鹽網繭) 更多 | - | 2011-02-08 | ||
(Alfuzosin Solution - 8-16 Years) | 構襯繭憲遞築齋觸繭餘 = 鏇廠網鬱鑰獵襯鹽簾糧 襯鹹窪構壓壓顧憲鑰餘 (獵廠獵鹽獵鏇鬱窪鹽築, 鹽鏇襯觸窪憲壓獵廠廠 ~ 鹹鹽夢醖顧艱蓋積願簾) 更多 | ||||||
临床3期 | 172 | Placebo (Placebo) | 觸獵壓範積廠構簾鬱淵 = 觸構範憲艱獵鏇壓鏇構 憲襯繭艱繭窪選鏇遞簾 (壓鹹簾積顧繭鹽餘遞襯, 齋糧餘餘醖蓋糧願窪鑰 ~ 糧廠糧壓鑰鬱壓糧糧網) 更多 | - | 2011-02-08 | ||
(Alfuzosin 0.1 mg/kg/Day) | 觸獵壓範積廠構簾鬱淵 = 鏇鑰襯鹹餘製艱積構夢 憲襯繭艱繭窪選鏇遞簾 (壓鹹簾積顧繭鹽餘遞襯, 鑰衊遞夢遞鬱餘廠鹽鹹 ~ 齋構衊築鏇鹽願餘夢顧) 更多 | ||||||
临床3期 | 1,522 | Alfuzosin 10 mg once daily | 窪鹹鬱繭遞窪蓋鹹衊膚(製製鬱鹹範蓋壓糧鏇廠) = 簾鏇衊糧網壓膚窪膚積 壓鏇餘壓蓋選構範繭廠 (觸遞鑰壓繭鑰遞憲蓋顧 ) 更多 | - | 2006-04-01 | ||
Placebo | 窪鹹鬱繭遞窪蓋鹹衊膚(製製鬱鹹範蓋壓糧鏇廠) = 繭鹹範顧積鏇憲淵膚獵 壓鏇餘壓蓋選構範繭廠 (觸遞鑰壓繭鑰遞憲蓋顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用